{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T07:02:45Z","timestamp":1779692565421,"version":"3.53.1"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The management of generalized myasthenia gravis (gMG) poses a therapeutic challenge. Efgartigimod, a neonatal Fc receptor (FcRn) inhibitor, has significant efficacy in patients with positive acetylcholine receptor (AChR) antibodies. However, approximately 30% of patients exhibit a poor early response. This study aimed to explore whether the complement C5 inhibitor, eculizumab, can bring clinical benefits to patients who have a poor early response to efgartigimod, thereby investigating potential sequential treatment strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We first conducted a prospective study to rigorously evaluate and longitudinally follow up 103 patients with gMG who received one treatment cycle of efgartigimod, ultimately enrolling 18 patients who demonstrated an inadequate response to the therapy. Then, these patients received eculizumab induction (900 mg weekly for four weeks) followed by maintenance dosing (1200 mg every two weeks or extended to once every three weeks). Clinical outcomes were assessed using MG-specific activities of daily living (MG-ADL) and quantitative myasthenia gravis (QMG) scores. Safety was evaluated through adverse event reporting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Significant clinical improvements were observed during the induction phase, with mean MG-ADL scores demonstrating a reduction from 7.9 \u00b1 3.9 before eculizumab to 2.6 \u00b1 1.7 [-5.3 (95% CI: -7.6 to -3.0); P &amp;lt; 0.001], while QMG scores dropped from 14.1 \u00b1 6.6 to 6.5 \u00b1 3.2 [-7.4 (95% CI: -10.2 to -4.7); P &amp;lt; 0.001]. All patients achieved clinically meaningful improvement (\u22652-point MG-ADL reduction), with four patients reaching minimal symptom expression (MSE, defined as an MG-ADL score \u22641-point) by week 4. Among the 12 patients who completed the 16-week follow-up, seven patients (58.3%) achieved minimal symptom expression. Glucocorticoid doses were successfully reduced to \u22645mg per day in seven patients. Two mild adverse events (urinary tract infection and limb edema) were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Eculizumab exhibited rapid and significant efficacy in patients with gMG who were poor early response to efgartigimod, and exhibited a favorable safety profile. These findings suggest that complement inhibition may serve as a potential sequential therapy when FcRn antagonist modulation failure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1730742","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T06:05:00Z","timestamp":1779689100000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world efficacy of eculizumab in generalized myasthenia gravis patients with poor early response to efgartigimod: a prospective cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Xueting","family":"An","sequence":"first","affiliation":[{"name":"Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijie","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital","place":["Tianjin, China"]},{"name":"Department of Neurology, The Affiliated Hospital of Xuzhou Medical University","place":["Xuzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Affiliated Hospital of Xuzhou Medical University","place":["Xuzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Affiliated Hospital of Xuzhou Medical University","place":["Xuzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/nejmra1602678","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000003570","article-title":"International consensus guidance for management of myasthenia gravis: Executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/acn3.51706","article-title":"The systemic inflammation markers as possible indices for predicting respiratory failure and outcome in patients with myasthenia gravis","volume":"10","author":"Huang","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1177\/17562864221080520","article-title":"Factors affecting minimal manifestation status induction in myasthenia gravis","volume":"15","author":"Li","year":"2022","journal-title":"Ther Adv Neurol Disord"},{"key":"B5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/mus.27832","article-title":"Myasthenic crisis","volume":"68","author":"Claytor","year":"2023","journal-title":"Muscle Nerve"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16229","article-title":"Generalized myasthenia gravis with acetylcholine receptor antibodies: A guidance for treatment","volume":"31","author":"Gilhus","year":"2024","journal-title":"Eur J Neurol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1177\/1756285617749134","article-title":"When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies","volume":"11","author":"Mantegazza","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2024-334086","article-title":"Efgartigimod efficacy and safety in refractory myasthenia gravis: UK's first real-world experience","volume":"96","author":"Moniz Dion\u00edsio","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-020-0400-0","article-title":"Complement in neurological disorders and emerging complement-targeted therapeutics","volume":"16","author":"Dalakas","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.13522","article-title":"Myasthenia gravis: the role of complement at the neuromuscular junction","volume":"1412","author":"Howard","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0875-9","article-title":"Eculizumab: A review in generalized myasthenia gravis","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12569-w","article-title":"United States clinical practice experience with eculizumab in myasthenia gravis: symptoms, function, and immunosuppressant therapy use","volume":"271","author":"Habib","year":"2024","journal-title":"J Neurol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/17562864211001995","article-title":"Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance","volume":"14","author":"Murai","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27476","article-title":"Utilization of MG-ADL in myasthenia gravis clinical research and care","volume":"65","author":"Muppidi","year":"2022","journal-title":"Muscle Nerve"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23944","article-title":"Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis","volume":"49","author":"Sanders","year":"2014","journal-title":"Muscle Nerve"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27381","article-title":"Rethinking the utility of acetylcholine receptor antibody titer as a pharmacodynamic biomarker for myasthenia gravis","volume":"64","author":"Lee","year":"2021","journal-title":"Muscle Nerve"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2203","article-title":"No correlation between acetylcholine receptor antibody concentration and individual clinical symptoms of myasthenia gravis: A systematic retrospective study involving 67 patients","volume":"11","author":"Wang","year":"2021","journal-title":"Brain Behav"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10061360","article-title":"Complement activation profile in myasthenia gravis patients: perspectives for tailoring anti-complement therapy","volume":"10","author":"Iacomino","year":"2022","journal-title":"Biomedicines"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1177\/17562864241309431","article-title":"Eculizumab in thymoma-associated myasthenia gravis: a real-world cohort study","volume":"17","author":"Jin","year":"2024","journal-title":"Ther Adv Neurol Disord"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1715486","article-title":"Efgartigimod non-responders after the first treatment cycle in generalized myasthenia gravis: a retrospective analysis of predictive factors","volume":"16","author":"Niu","year":"2025","journal-title":"Front Neurol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11222-8","article-title":"Eculizumab as a fast-acting rescue therapy in a refractory myasthenic crisis: a case report","volume":"269","author":"Strano","year":"2022","journal-title":"J Neurol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-023-06900-y","article-title":"Starting eculizumab as rescue therapy in refractory myasthenic crisis","volume":"44","author":"Vinciguerra","year":"2023","journal-title":"Neurol Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10428-6","article-title":"Complement inhibition initiated recovery of a severe myasthenic crisis with COVID-19","volume":"268","author":"Hofstadt-van Oy","year":"2021","journal-title":"J Neurol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1177\/17562864241261602","article-title":"The safety and efficacy profile of eculizumab in myasthenic crisis: a prospective small case series","volume":"17","author":"Song","year":"2024","journal-title":"Ther Adv Neurol Disord"},{"key":"B27","doi-asserted-by":"publisher","first-page":"28394","DOI":"10.1038\/s41598-024-79918-7","article-title":"Efgartigimod versus intravenous immunoglobulin in the treatment of patients with impending myasthenic crisis","volume":"14","author":"Ma","year":"2024","journal-title":"Sci Rep"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1418503","article-title":"Efgartigimod as a promising add-on therapy for myasthenic crisis: a prospective case series","volume":"15","author":"Song","year":"2024","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14228205","article-title":"Complement inhibitors in generalized myasthenia gravis: comparison of administration schedules, efficacy, and safety","volume":"14","author":"Di Martino","year":"2025","journal-title":"J Clin Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1730742\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T06:05:01Z","timestamp":1779689101000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1730742\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2026.1730742"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1730742","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"article-number":"1730742"}}